Last updated: February 13, 2026
Product Overview
NDC 00480-7168 corresponds to Raxibacumab, a monoclonal antibody approved by the FDA in December 2012 for the treatment and prophylaxis of inhalational anthrax caused by Bacillus anthracis.[1] It is marketed primarily for biodefense, with limited indications in the civilian sector. Its commercial viability depends heavily on government stockpiling, biodefense budgets, and potential niche clinical applications.
Market Size and Demand Drivers
Military and Government Stockpiling: U.S. Department of Health and Human Services (HHS) maintains strategic stockpiles of biodefense products, including Raxibacumab, influencing demand. The U.S. government contracted strategic reserves at approximately $1.8 billion for biodefense drugs in FY 2021.[2]
Biodefense Spending: The global biodefense market was valued at around $9 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 6-8% through 2030 due to increased biological threats.[3] Raxibacumab’s market share depends on government procurement policies and international biodefense initiatives.
Limited Clinical Commercial Use: Outside biodefense, Raxibacumab has negligible cross-over to civilian infectious disease markets. It faces competition from alternative anthrax therapies like Antibiotics (ciprofloxacin, doxycycline) and experimental monoclonals.
Pricing and Procurement: The U.S. government's procurement price for Raxibacumab has been approximately $1.377 per mg, equating to roughly $3,000 per treatment course (~2–3 grams based on dosing).[4] Commercial pricing remains undefined but is unlikely to surpass government negotiated prices, considering the niche application.
Market Competition
Biodefense Monoclonal Antibodies: Rivals include Obiltoxaximab, also approved for inhalation anthrax, with similar indications and pricing. The choice between them depends on supply agreements and supply chain logistics.[5]
Antibiotic Treatments: Ciprofloxacin and doxycycline dominate the market for anthrax post-exposure and treatment, with unit costs significantly lower but less targeted than monoclonals.
Pipeline Developments: No substantial competitors are in late-stage clinical trials as of 2023, limiting competitive pressure but also indicating limited market expansion prospects.
Price Projections (2023–2030)
Base Case: The current pricing for Raxibacumab remains at approximately $3,000 per dose. Given the product's niche and reliance on government procurement, prices are unlikely to see significant fluctuation unless new indications or changes in procurement policies occur.
Scenario 1: Increased Biodefense Spending — If biodefense budgets increase by 10-15% annually, demand could grow, pushing unit sales. Prices might remain stable or rise slightly, around 5% annually due to inflation and supply chain costs.
Scenario 2: Policy Changes and Generic Entry — Generic versions or alternative therapies could lower prices by 10-20% from 2025 onward if biosimilars enter the market or if the government negotiates lower prices due to budget constraints.
Scenario 3: International Market Expansion — Limited due to biosafety regulations and low demand outside the United States. If international biodefense funding grows, revenues could see marginal increases, but large-scale sales are unlikely before 2030.
| Year |
Estimated Price per Treatment Course |
Estimated Annual Units Sold |
Market Revenue (USD Millions) |
| 2023 |
$3,000 |
20,000 |
$60 |
| 2025 |
$3,150 (5% inflation) |
25,000 |
$78.75 |
| 2028 |
$3,600 (assuming slight demand growth and inflation) |
30,000 |
$108 |
| 2030 |
$3,900 (if demand increases) |
35,000 |
$136.5 |
Note: These figures presuppose steady procurement primarily driven by U.S. government needs.
Risks and Uncertainties
- Changes in biodefense policy or budget allocations impact demand.
- Potential development of more effective or cheaper treatments.
- International approval hurdles and low market penetration.
- The inherent unpredictability of biodefense market size and stockpile renewals.
Key Takeaways
- Raxibacumab operates primarily in a niche, government-driven biodefense market.
- Current prices hover around $3,000 per course, with limited potential for rapid increase.
- Demand growth hinges on biodefense budgets and international collaboration.
- Competitive landscape is limited but evolving with alternative treatments and policy shifts.
- Long-term revenue projections remain constrained by the niche market and funding cycles.
FAQs
-
How stable is the demand for Raxibacumab?
Demand is primarily dependent on U.S. government biodefense stockpiling and is relatively stable but unpredictable due to policy changes.
-
What factors could influence future pricing?
Increases in biodefense budgets, development of biosimilars, or supply chain improvements could affect pricing.
-
How does Raxibacumab compare price-wise to competitors?
Pricing is similar to Obiltoxaximab; both hover around $3,000 per treatment course. Actual prices depend on procurement agreements.
-
Is there potential for broader clinical use?
Currently limited; potential exists if new indications are approved, but no significant clinical advances are expected before 2030.
-
What role do international markets play?
Minimal at present due to regulatory, safety, and demand constraints. Future growth depends on global biological threat responses and funding.
References
- FDA. Raxibacumab Approval Letter. 2012.
- HHS Budget. Fiscal Year 2021.
- MarketsandMarkets. Biodefense Market By Product, 2022.
- BARDA Pricing Data. 2021.
- CDC. Anthrax Treatments and Prevention. 2023.
